Positron emission tomography and positron emission tomography-CT evaluation for recurrent papillary thyroid carcinoma: Meta-analysis and literature review

Head and Neck

Volumn 33, Issue 4, 2011, Pages 562-565

  Miller, Mia E ^a   Chen, Qiaolin ^a   Elashoff, David ^a   Abemayor, Elliot ^a,b   St John, Maie ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cancer surveillance; fluorodeoxyglucose; papillary thyroid carcinoma; PET; PET CT; well differentiated thyroid carcinoma

Indexed keywords

ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE SURVEILLANCE; HUMAN; INTERMETHOD COMPARISON; META ANALYSIS; PAPILLARY CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; THYROID CARCINOMA;

ADENOCARCINOMA, FOLLICULAR; CARCINOMA, PAPILLARY; HUMANS; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79952925203     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21492     Document Type: Article

References (26)

1. Giammarile F, Hafdi Z, Bournaud C, et al. Is [18F]-2-fluoro-2-deoxy-d- glucose (FDG) scintigraphy with non-dedicated positron emission tomography useful in the diagnostic management of suspected metastatic thyroid carcinoma in patients with no detectable radioiodine uptake? Eur J Endocrinol 2003; 149: 293-300. (Pubitemid 37304699)
2. Feine U, Lietzenmayer R, Hanke JP, Held J, Wöhrle H, Müller-Schauenburg W,. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996; 37: 1468-1472. (Pubitemid 26321624)
3. Conti PS, Durski JM, Bacqai F, Grafton ST, Singer PA,. Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. Thyroid 1999; 9: 797-804. (Pubitemid 29409664)
4. Agrawal A, Hall NC, Ringel MD, Povoski SP, Martin EW Jr,. Combined use of perioperative TSH-stimulated (18)F-FDG PET/CT imaging and gamma probe radioguided surgery to localize and verify resection of iodine scan-negative recurrent thyroid carcinoma. Laryngoscope 2008; 118: 2190-2194.
5. Dalgorf D, Higgins KM, Ehrlich L,. PET/CT fusion technology: its role in managing recurrent, well-differentiated thyroid cancer. Can J Surg 2008; 51: E21-22.
6. Grant CS, Thompson GB, Farley DR, Richards ML, Mullan BP, Hay ID,. The value of positron emission tomography in the surgical management of recurrent papillary thyroid carcinoma. World J Surg 2008; 32: 708-715.
7. Grünwald F, Kälicke T, Feine U, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999; 26: 1547-1552. (Pubitemid 30010291)
8. Iagaru A, Masamed R, Singer PA, Conti PS,. 2-Deoxy-2-[18F]fluoro-D- glucose-positron emission tomography and positron emission tomography/computed tomography diagnosis of patients with recurrent papillary thyroid cancer. Mol Imaging Biol 2006; 8: 309-314. (Pubitemid 44446025)
9. Nahas Z, Goldenberg D, Fakhry C, et al. The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope 2005; 115: 237-243. (Pubitemid 40216695)
10. Saab G, Driedger AA, Pavlosky W, et al. Thyroid-stimulating hormone-stimulated fused positron emission tomography/computed tomography in the evaluation of recurrence in 131I-negative papillary thyroid carcinoma. Thyroid 2006; 16: 267-272.
11. Zimmer LA, McCook B, Meltzer C, et al. Combined positron emission tomography/computed tomography imaging of recurrent thyroid cancer. Otolaryngol Head Neck Surg 2003; 128: 178-184. (Pubitemid 36314864)
12. Choi MY, Chung JK, Lee HY, et al. The clinical impact of 18F-FDG PET in papillary thyroid carcinoma with a negative 131I whole body scan: a single-center study of 108 patients. Ann Nucl Med 2006; 20: 547-552.
13. Frilling A, Görges R, Tecklenborg K, et al. Value of preoperative diagnostic modalities in patients with recurrent thyroid carcinoma. Surgery 2000; 128: 1067-1074.
14. Chung JK, So Y, Lee JS, et al. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. J Nucl Med 1999; 40: 986-992. (Pubitemid 29269219)
15. Yeo JS, Chung JK, So Y, et al. F-18-fluorodeoxyglucose positron emission tomography as a presurgical evaluation modality for I-131 scan-negative thyroid carcinoma patients with local recurrence in cervical lymph nodes. Head Neck 2001; 23: 94-103. (Pubitemid 32060661)
16. Freudenberg LS, Antoch G, Frilling A, et al. Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET. Eur J Nucl Med Mol Imaging 2008; 35: 950-957.
17. Palmedo H, Bucerius J, Joe A, et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 2006; 47: 616-624. (Pubitemid 46768462)
18. Shammas A, Degirmenci B, Mountz JM, et al. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med 2007; 48: 221-226. (Pubitemid 47555347)
19. Dahele H, Ung YC, Ehrlich L, Silverberg J, Balogh J, Wong CS,. 18F-fluorodeoxyglucose positron emission tomography-computed tomography for suspected recurrent papillary thyroid cancer: early experience at Sunnybrook Health Sciences Centre. J Otolaryngol Head Neck Surg 2008; 37: 712-717.
20. Zoller M, Kohlfuerst S, Igerc I, et al. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality? Eur J Nucl Med Mol Imaging 2007; 34: 487-495. (Pubitemid 46426997)
21. Frilling A, Tecklenborg K, Görges R, Weber F, Clausen M, Broelsch EC,. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Ann Surg 2001; 234: 804-811. (Pubitemid 33117201)
22. Mirallié E, Guillan T, Bridji B, et al. Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma. Surgery 2007; 142: 952-958; discussion 952-958. (Pubitemid 350193249)
23. Dong MJ, Liu ZF, Zhao K, et al. Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis. Nucl Med Commun 2009; 30: 639-650.
24. Shie P, Cardarelli R, Sprawls K, Fulda KG, Taur A,. Systematic review: prevalence of malignant incidental thyroid nodules identified on fluorine-18 fluorodeoxyglucose positron emission tomography. Nucl Med Commun 2009; 30: 742-748.
25. van Tol KM, Jager PL, Piers DA, et al. Better yield of (18)fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation. Thyroid 2002; 12: 381-387. (Pubitemid 34602596)
26. Razfar A, Branstetter BF IV, Christopoulos A, et al. Clinical usefulness of positron emission tomography-computed tomography in recurrent thyroid carcinoma. Arch Otolaryngol Head Neck Surg 2010; 136: 120-125.